{
"info": {
"nct_id": "NCT05669482",
"official_title": "A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas",
"inclusion_criteria": "* Male or female subjects ≥ 18 years of age\n* Histologic or cytologic evidence of metastatic pancreatic ductal adenocarcinoma.\n* An Eastern Cooperative Group (ECOG) performance status ≤ 1\n* Measurable disease according to RECIST 1.1\n* Adequate organ function\n* Adequate cardiac function\n* Agreement to use highly effective method of contraceptive\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Patients with pancreatic neuroendocrine tumors\n* Prior or concomitant treatment for metastatic pancreatic ductal adenocarcinoma\n* Prior treatment with inhibitors of the RAS /MAPK pathway [e.g. MEK inhibitors] or inhibitors of FAK\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks (excluding placement of vascular access)\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Concurrent ocular disorders\n* Active skin disorder that has required systemic therapy within the past 1 year\n* Patients with interstitial lung disease or pulmonary fibrosis or severe lung disease, pulmonary edema, and adult respiratory distress syndrome\n* Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Male or female subjects ≥ 18 years of age",
"criterions": [
{
"exact_snippets": "Male or female subjects",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"male",
"female"
]
}
]
},
{
"exact_snippets": "≥ 18 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Histologic or cytologic evidence of metastatic pancreatic ductal adenocarcinoma.",
"criterions": [
{
"exact_snippets": "Histologic or cytologic evidence of metastatic pancreatic ductal adenocarcinoma",
"criterion": "metastatic pancreatic ductal adenocarcinoma",
"requirements": [
{
"requirement_type": "evidence type",
"expected_value": [
"histologic",
"cytologic"
]
}
]
}
]
},
{
"line": "* An Eastern Cooperative Group (ECOG) performance status ≤ 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Group (ECOG) performance status ≤ 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "performance status",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Measurable disease according to RECIST 1.1",
"criterions": [
{
"exact_snippets": "Measurable disease according to RECIST 1.1",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "criteria",
"expected_value": "RECIST 1.1"
}
]
}
]
},
{
"line": "* Adequate organ function",
"criterions": [
{
"exact_snippets": "Adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Adequate cardiac function",
"criterions": [
{
"exact_snippets": "Adequate cardiac function",
"criterion": "cardiac function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Agreement to use highly effective method of contraceptive",
"criterions": [
{
"exact_snippets": "Agreement to use highly effective method of contraceptive",
"criterion": "contraceptive method",
"requirements": [
{
"requirement_type": "effectiveness",
"expected_value": "highly effective"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients with pancreatic neuroendocrine tumors",
"criterions": [
{
"exact_snippets": "pancreatic neuroendocrine tumors",
"criterion": "tumor type",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "pancreatic neuroendocrine tumors"
}
]
}
]
},
{
"line": "* Prior or concomitant treatment for metastatic pancreatic ductal adenocarcinoma",
"criterions": [
{
"exact_snippets": "Prior or concomitant treatment for metastatic pancreatic ductal adenocarcinoma",
"criterion": "treatment for metastatic pancreatic ductal adenocarcinoma",
"requirements": [
{
"requirement_type": "timing",
"expected_value": [
"prior",
"concomitant"
]
}
]
}
]
},
{
"line": "* Prior treatment with inhibitors of the RAS /MAPK pathway [e.g. MEK inhibitors] or inhibitors of FAK",
"criterions": [
{
"exact_snippets": "Prior treatment with inhibitors of the RAS /MAPK pathway [e.g. MEK inhibitors]",
"criterion": "prior treatment with RAS/MAPK pathway inhibitors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Prior treatment with ... inhibitors of FAK",
"criterion": "prior treatment with FAK inhibitors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* History of prior malignancy, with the exception of curatively treated malignancies",
"criterions": [
{
"exact_snippets": "History of prior malignancy",
"criterion": "prior malignancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "curatively treated malignancies",
"criterion": "curatively treated malignancies",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Major surgery within 4 weeks (excluding placement of vascular access)",
"criterions": [
{
"exact_snippets": "Major surgery within 4 weeks",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "excluding placement of vascular access",
"criterion": "placement of vascular access",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
}
]
},
{
"line": "* Concurrent heart disease or severe obstructive pulmonary disease",
"criterions": [
{
"exact_snippets": "Concurrent heart disease",
"criterion": "heart disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "severe obstructive pulmonary disease",
"criterion": "obstructive pulmonary disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
}
]
},
{
"line": "* Concurrent ocular disorders",
"criterions": [
{
"exact_snippets": "Concurrent ocular disorders",
"criterion": "ocular disorders",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Active skin disorder that has required systemic therapy within the past 1 year",
"criterions": [
{
"exact_snippets": "Active skin disorder that has required systemic therapy within the past 1 year",
"criterion": "skin disorder",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
},
{
"requirement_type": "treatment",
"expected_value": "systemic therapy within the past 1 year"
}
]
}
]
},
{
"line": "* Patients with interstitial lung disease or pulmonary fibrosis or severe lung disease, pulmonary edema, and adult respiratory distress syndrome",
"criterions": [
{
"exact_snippets": "interstitial lung disease",
"criterion": "interstitial lung disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "pulmonary fibrosis",
"criterion": "pulmonary fibrosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "severe lung disease",
"criterion": "severe lung disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "pulmonary edema",
"criterion": "pulmonary edema",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "adult respiratory distress syndrome",
"criterion": "adult respiratory distress syndrome",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy",
"criterions": [
{
"exact_snippets": "Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy",
"criterion": "SARS-Cov2 infection",
"requirements": [
{
"requirement_type": "time since infection",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}